Molecular oncology of lung cancer

被引：55

作者：

Toyooka S. ^{[1
]}

Mitsudomi T. ^{[2
]}

Soh J. ^{[1
]}

Aokage K. ^{[1
]}

Yamane M. ^{[1
]}

Oto T. ^{[1
]}

Kiura K. ^{[3
]}

Miyoshi S. ^{[1
]}

机构：

[1] Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558

[2] Department of Thoracic Surgery, Aichi Cancer Center, Nagoya

[3] Department of Hematology Oncology, Allergy and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama

来源：

General Thoracic and Cardiovascular Surgery | 2011年 / 59卷 / 8期

关键词：

Biology; Lung cancer; Molecular oncology;

D O I：

10.1007/s11748-010-0743-3

中图分类号：

学科分类号：

摘要：

Progress in genetic engineering has made it possible to elucidate the molecular biological abnormalities in lung cancer. Mutations in KRAS and P53 genes, loss of specific alleles, and DNA methylation of the tumor suppressor genes were the major abnormalities investigated between 1980 and the 2000s. In 2004, mutations in the epidermal growth factor receptor (EGFR) gene that cause oncogene addiction were discovered in non-small-cell lung cancers (NSCLCs), especially in adenocarcinomas. Because they are strongly associated with sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a great deal of knowledge has been acquired in regard to both EGFR and other genes in the EGFR family and their downstream genes. Moreover, in 2007 the existence of the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion gene was discovered in NSCLC; and the same as EGFR-TKIs, ALK inhibitors are being found to be highly effective in lung cancers that have this translocation. These discoveries graphically illustrate that molecular biological findings are directly linked to the development of clinical oncology and to improving the survival rates of lung cancer patients. Here, we review the remarkable progress in molecular biological knowledge acquired thus far in regard to lung cancer, especially NSCLC, and the future possibilities. © 2011 The Japanese Association for Thoracic Surgery.

引用

页码：527 / 537

页数：10

共 93 条

[11]

Inukai M., Toyooka S., Ito S., Asano H., Ichihara S., Soh J., Suehisa H., Ouchida M., Aoe K., Aoe M., Kiura K., Shimizu N., Date H., Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer, Cancer Research, 66, 16, pp. 7854-7858, (2006)

[12]

Soh J., Okumura N., Lockwood W.W., Yamamoto H., Shigematsu H., Zhang W., Et al., Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells, PLoS One, (2009)

[13]

Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn Jr. P.A., Varella-Garcia M., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, Journal of the National Cancer Institute, 97, 9, pp. 643-655, (2005)

[14]

Ichihara S., Toyooka S., Fujiwara Y., Hotta K., Shigematsu H., Tokumo M., Et al., The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer, Int J Cancer, 120, pp. 1239-1247, (2007)

[15]

Gandhi J., Zhang J., Xie Y., Soh J., Shigematsu H., Zhang W., Et al., Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines, PLoS One, 4, (2009)

[16]

Shigematsu H., Gazdar A.F., Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, International Journal of Cancer, 118, 2, pp. 257-262, (2006)

[17]

Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., Rossi E., Ludovini V., Gregorc V., Toschi L., Franklin W.A., Crino L., Gazdar A.F., Bunn Jr. P.A., Hirsch F.R., Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients, Journal of Clinical Oncology, 23, 22, pp. 5007-5018, (2005)

[18]

Soh J., Toyooka S., Ichihara S., Fujiwara Y., Hotta K., Suehisa H., Kobayashi N., Ichimura K., Aoe K., Aoe M., Kiura K., Date H., Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer, International Journal of Cancer, 121, 5, pp. 1162-1167, (2007)

[19]

Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Joon O.P., Lindeman N., Gale C.-M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 5827, pp. 1039-1043, (2007)

[20]

Kubo T., Yamamoto H., Lockwood W.W., Valencia I., Soh J., Peyton M., Et al., MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors, Int J Cancer, 124, pp. 1778-1784, (2009)

← 1 2 3 4 5 6 7 8 9 10 →